NAD+
Endogenous coenzyme; Not a peptide
Brief Overview: NAD+ is a coenzyme involved in energy metabolism, sirtuin activity, DNA repair, and cellular stress responses. It appears in peptide-clinic settings because it is often injected or infused, not because it is chemically a peptide. Evidence lens: NAD biology is real, but blood infusion effects do not map neatly to intracellular NAD pools in every tissue. Symptoms during infusion, changes in fatigue, and biomarker shifts should not be overinterpreted as global cellular rejuvenation. How to read this: if you're new, distinguish NAD+ itself from precursors such as NR, NMN, niacin, and tryptophan-pathway support. Once you're past the basics, think about rate of infusion, methylation demand, liver metabolism, and objective outcomes rather than “felt energy” alone.
- NAD+ is a central redox coenzyme involved in energy metabolism, sirtuin biology, DNA-repair signaling, and cellular stress response.
- NAD+ is a coenzyme rather than a peptide, but it belongs in the guide because it is often used in the same clinics and stacks. NAD+ itself is distinct from precursors like NR, NMN, niacin, and tryptophan-pathway strategies.
- NAD+ participates in oxidation-reduction reactions and serves as substrate for enzymes such as sirtuins and PARPs.
- NAD biology supports redox reactions, sirtuins, PARPs, CD38-related consumption, and mitochondrial metabolism. Raising NAD markers does not automatically mean improved clinical outcomes. The mechanism here is a plausibility map, not proof of a clinical outcome.
- Claims about aging, long COVID, addiction recovery, and mitochondrial optimization are broad and need endpoint-specific human evidence.
- IV NAD+ clinic claims are not established therapy without clinical-trial support.
- Human evidence is stronger for some oral precursors raising NAD-related metabolites than for broad disease or anti-aging outcomes. IV NAD+ has community and clinic use but less rigorous endpoint evidence. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.
Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.
- Protocol 1: Clinical/IV Protocols [Clinical/Human Trial]; Route: IV Infusion (Slow drip); Dose: 250 mg – 1,000 mg; Frequency: 1 to 3 sessions (Loading); Duration: 4 to 10 days (intensive); Max: 1,500 mg (under supervision); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 2: Common Biohacker Protocols [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC) Injection; Dose: 50 mg – 200 mg; Frequency: 2 to 3 times per week; Duration: 4 to 8 weeks; Max: 250 mg (daily in loading); Titration/loading: Loading example: 100 mg daily for 7-10 days, then 100 mg twice weekly.; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 3: Oral precursors [Research/Experimental]; Route: Oral NMN or NR; Dose: 300 mg - 1,000 mg daily; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Route and infusion rate matter greatly for tolerability. Oral precursor dosing does not convert into IV NAD+ dosing or vice versa. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.
- Time until steady state: not meaningfully calculable as a simple drug half-life.
- Half-life basis: Endogenous coenzyme with rapid extracellular metabolism and intracellular pool dynamics. Intracellular NAD biology does not map cleanly onto a plasma steady-state model.
- Beginner translation: this is a deliberately conservative read. A missing steady-state number does not mean the compound has no effect; It means the available human PK data are not strong enough to justify a precise accumulation estimate for common use patterns.
- Half-life: Systemic half-life is very short (estimated minutes). However, the increase in the intracellular NAD+ “pool” can persist for several days.
- Delivery: IV provides 100% bioavailability but must be infused slowly (2-4 hours) to avoid intense side effects. Subcutaneous injection is sometimes used outside clinics, but home self-administration is not a validated protocol and should involve clinician oversight.
- NAD+ metabolism is compartmentalized; Blood levels and intracellular tissue effects are not the same. Precursors may work by different transport and salvage-pathway steps. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.
- CD38 Inhibitors: Apigenin and quercetin are proposed to slow CD38-mediated NAD+ breakdown, but this stacking is investigational and not clinically validated.
- Sirtuin Activators: Often paired with Resveratrol or Pterostilbene to ensure the newly provided NAD+ is effectively utilized by the sirtuin longevity pathways.
- Peptide Synergy: Frequently stacked with MOTS-c (for mitochondrial power) or CJC-1295/Ipamorelin (to maximize growth hormone-related repair).
- Often paired with glutathione, methyl donors, mitochondrial peptides, exercise, or fasting protocols. Consider methylation and B-vitamin context when using high-dose precursor approaches. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.
The “NAD+ Sickness”: If injected or infused too quickly, users experience a distinctive sensation of chest pressure, stomach cramping, and nausea. This is temporary and subsides within minutes of stopping the drip or injection.
- Active Malignancy: Like all therapies that boost cellular energy, there is a theoretical concern that NAD+ could fuel the high metabolic demands of existing cancer cells.
- Methylation Depletion: High-dose NAD+ can “soak up” methyl groups. Many practitioners recommend taking TMG (Trimethylglycine) or a B-Complex to prevent methyl depletion.
- Common issues include nausea, flushing, chest tightness/anxiety during rapid infusions, methylation imbalance symptoms, and uncertain long-term effects in cancer contexts. Infusion quality matters. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.
Intracellular NAD+ Testing: Modern “at-home” dried blood spot tests (e.g., Jinfiniti) now allow users to measure their actual NAD+ levels in micromolar (mcM) units.
- Inflammatory Markers: Tracking hs-CRP to see the systemic anti-inflammatory effects of sirtuin activation. Energy &
- Sleep: Subjective tracking of “afternoon slumps” and deep sleep quality.
- Track energy/fatigue, sleep, heart-rate symptoms during infusions, liver enzymes if high-dose supplements are used, methylation markers when relevant, and glucose/lipids for metabolic goals. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.
- FDA: Not approved as a drug for anti-aging.
- However, it is widely available in “Wellness Clinics” and via compounding pharmacies as a supplement or injectable.
- 2026 Update: Some longevity clinics now offer whole-blood NAD+ testing, but it remains investigational rather than an established, evidence-based clinical standard.
- NAD+ and precursors appear in supplement, compounding, and clinic markets with different regulatory statuses. Claims determine regulatory risk. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.